Eli Lilly Recalls Glucagon that May Fail to Treat Severe Hypoglycemia
October 25, 2021Cutaquig Indication Now Includes Treatment of Pediatric Patients
October 27, 2021October 25, 2021 – XipereTM (triamcinolone acetonide injectable suspension) has been approved by the U.S. FDA for suprachoroidal use to treat macular edema associated with uveitis. It is the first and only medication in the United States specifically approved to treat macular edema associated with uveitis, and the first and only medication FDA-approved for suprachoroidal use.
- Macular edema occurs when fluid accumulates in the retina and is the leading cause of blindness in patients who have uveitis, a type of eye inflammation.
- Xipere contains a corticosteroid that is administered by a healthcare professional as a single 4mg injection into the suprachoroidal space using a proprietary SCS Microinjector®.
- Injecting medication into the suprachoroidal space, which sits beneath the sclera (the white portion of the eye) and extends toward the back of the eye, may allow more targeted delivery compared to an intravitreal injection, a current standard of care that delivers medication to a different area inside the eye. This may reduce the risk of adverse events such as cataracts and increased pressure inside of the eye.
- Manufactured by Bausch + Lomb in coordination with Clearside Biomedical, Xipere is expected to launch during the first quarter of 2022.